Sacubitril-valsartan treatment furtherly improves response to intermittent parenteral levosimendan in ambulatory patients with advanced heart failure with reduced ejection fraction
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy